Natus Medical Incorporated (NASDAQ:NTUS) changed 0.88% to recent value of $19.52. The stock transacted 654654 shares during most recent day however it has an average volume of 180.50K shares. It spotted trading -44.05% off 52-week high price. On the other end, the stock has been noted 3.23% away from the low price over the last 52-weeks.
On March 20, 2020, Natus Medical Incorporated (NASDAQ:NTUS) a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, declared the appointment of Ilan Daskal, current Chief Financial Officer & Executive Vice President of Bio-RAD Laboratories, to its board of directors and audit committee effective March 19, 2020. The Company will also nominate Mr. Daskal at its 2020 Annual Meeting of Stockholders.
We are pleased to welcome Ilan as a new independent director to the Natus board, said Barbara R. Paul, M.D., Chairperson of Natus’ board of directors. Ilan’s extensive financial and operational experience complement our current board members, strengthening the board and company as we focus on driving value for our customers, employees and stockholders. The Natus board is committed to regular evaluation of its composition, to refreshment and to building a board with a mix of skills, expertise and experience that supports stockholder value creation.
Natus’ other directors consist of Barbara R. Paul, M.D., former Chief Medical Officer of Community Health Systems, Joshua Levine, President and CEO of Accuray, Incorporated, Kenneth Ludlum, former CFO of CareDx, Lisa Wipperman Heine, President & CEO of PreCardia, Alice D. Schroeder, former CEO and Chair of WebTuner Corporation, Thomas J. Sullivan, President and CEO of A&E Medical Corporation, and Jonathan Kennedy, President and CEO of the Company.
NTUS has a gross margin of 58.90% and an operating margin of -3.20% while its profit margin remained -3.20% for the last 12 months. Its earnings per share (EPS) expected to touch remained -7.40% for this year while earning per share for the next 5-years is expected to reach at 22.00%.
The company has 41.22M of outstanding shares and 33.51M shares were floated in the market. According to the most recent quarter its current ratio was 1.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of -24.31% from the mean of 20 days, -34.47% from mean of 50 days SMA and performed -34.73% from mean of 200 days price. Company’s performance for the week was -19.00%, -35.32% for month and YTD performance remained -40.83%.